Lilly posts $19.8B first-quarter revenue as Mounjaro and Zepbound reach $12.8B
Self-pay made up about 45% of Zepbound prescriptions, and US realized price fell 7% in the quarter, the company said on its earnings call.
The wire
- 01Eli Lilly reported Q1 2026 revenue of $19.8B, up 56% year over year, with Mounjaro and Zepbound contributing $12.8B combined and non-GAAP EPS of $8.55 versus $3.34.
- 02Foundayo (orforglipron) launched into pharmacies April 9 with roughly 20,000 patients treated as of the call, 80% of them new to the GLP-1 class, relevant to prescribers and dispensers tracking oral uptake.
- 03Management raised 2026 revenue guidance to $82B–$85B; executives flagged a 7% US price decline, about 10% excluding a one-time rebate adjustment, as gross margin slipped to 82%.
From the source
Read at tikr.comEli Lilly Reports $19.8B Q1 Revenue as GLP-1 Sales Surge 56% Year Over Year
Most investors never know if a stock is truly undervalued or overpriced. TIKR’s professional-grade valuation tools give you a clear, data-backed answer across 60,000+ stocks for free →